Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | MARS1 | P56192 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RPA1 | P27694 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | CTSA | P10619 | 1/20 | 0.33 |
| ▸ | EIF4E | P06730 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16700422 | 0.92 | KMO (0.39) | KMOCASP1MDM2GRIN2BABL1 | |
| SCHEMBL16709126 | 0.86 | CNR1 (0.36) | MAPTCNR2 | |
| SCHEMBL16700410 | 0.82 | KMO (0.38) | KMOCASP1MDM2GRIN2BABL1 | |
| SCHEMBL16700136 | 0.81 | MEN1 (0.35) | KMOMDM2MAPTCTSA | |
| SCHEMBL16699714 | 0.79 | CSNK1E (0.36) | KMOMDM2GRIN2BMARS1 | |
| SCHEMBL16709125 | 0.78 | CNR1 (0.36) | MAPTCNR2 | |
| SCHEMBL16700995 | 0.77 | CSNK1E (0.44) | — | |
| SCHEMBL16699357 | 0.77 | CSNK1E (0.41) | — | |
| SCHEMBL16699580 | 0.73 | KMO (0.39) | KMOCASP1MDM2GRIN2BABL1 | |
| SCHEMBL16709123 | 0.72 | KAT5 (0.35) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3068785-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-06-26 | — | — | EP | disclosed |
| EP-3068785-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-09-21 | — | — | EP | disclosed |
| US-20160122358-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-05 | — | — | US | disclosed |
| US-9273058-B2 | Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| WO-2015073763-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-21 | — | — | WO | disclosed |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122358-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | KMO 2351/4885CASP1 1485/4885MDM2 1297/4885 |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | KMO 2351/4885CASP1 1485/4885MDM2 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.